Oncocyte Announces August Investor Conferences Participation
Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, has announced its participation in two investor conferences this August. CEO Josh Riggs and CFO Andrea James will represent the company at:
1. The 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 12-13, 2024, where they plan to host meetings with investors.
2. The Sidoti Micro-Cap Virtual Conference on August 14-15, 2024. Oncocyte is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, and will also participate in one-on-one meetings.
Investors interested in scheduling meetings with Oncocyte's management team can contact their Needham or Sidoti representative or reach out to the company's IR contact directly.
Oncocyte Corp. (Nasdaq: OCX), un'azienda di tecnologia per la diagnostica molecolare, ha annunciato la sua partecipazione a due conferenze per investitori in agosto. Il CEO Josh Riggs e il CFO Andrea James rappresenteranno l'azienda in:
1. La 9ª Conferenza MedTech & Diagnostics 1×1 Virtuale di Needham, che si terrà il 12-13 agosto 2024, dove prevedono di incontrare investitori.
2. La Conferenza Virtuale Sidoti Micro-Cap, che si svolgerà dal 14 al 15 agosto 2024. Oncocyte è programmata per presentare mercoledì 14 agosto, dalle 13:00 alle 13:30 ET nel Track 3, e parteciperà anche a incontri one-on-one.
Gli investitori interessati a pianificare incontri con il team di gestione di Oncocyte possono contattare il loro rappresentante di Needham o Sidoti, oppure contattare direttamente il referente IR dell'azienda.
Oncocyte Corp. (Nasdaq: OCX), una empresa de tecnología en diagnóstico molecular, ha anunciado su participación en dos conferencias para inversores este agosto. El CEO Josh Riggs y la CFO Andrea James representarán a la empresa en:
1. La 9ª Conferencia Virtual MedTech & Diagnostics 1×1 de Needham, que se llevará a cabo del 12 al 13 de agosto de 2024, donde planean tener reuniones con inversores.
2. La Conferencia Virtual de Sidoti Micro-Cap, programada para el 14 y 15 de agosto de 2024. Oncocyte está programada para presentar el miércoles 14 de agosto, de 1:00 PM a 1:30 PM ET en la Pista 3, y también participará en reuniones uno a uno.
Los inversores interesados en programar reuniones con el equipo de gestión de Oncocyte pueden contactar a su representante de Needham o Sidoti, o comunicarse directamente con el contacto de IR de la empresa.
온코사이트 코퍼레이션(Nasdaq: OCX), 분자 진단 기술 회사가 이번 8월 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다. CEO 조시 리그스와 CFO 안드레아 제임스가 회사를 대표하여:
1. 2024년 8월 12일부터 13일까지 열리는 제9회 니덤 가상 메드테크 & 진단 1×1 컨퍼런스에서 투자자와 미팅을 진행할 예정입니다.
2. 2024년 8월 14일부터 15일까지 열리는 시도티 마이크로캡 가상 컨퍼런스에서 온코사이트는 8월 14일 수요일 오후 1시부터 1시 30분 ET까지 트랙 3에서 발표할 예정이며, 일대일 미팅에도 참여할 것입니다.
온코사이트의 경영진과 미팅을 희망하는 투자자는 니덤이나 시도티 대표에게 연락하거나 회사의 IR 연락처로 직접 연락할 수 있습니다.
Oncocyte Corp. (Nasdaq: OCX), une entreprise de technologie en diagnostic moléculaire, a annoncé sa participation à deux conférences pour investisseurs en août. Le PDG Josh Riggs et le CFO Andrea James représenteront la société lors des événements suivants :
1. La 9e Conférence Virtuelle MedTech & Diagnostics 1×1 de Needham qui aura lieu les 12 et 13 août 2024, où ils prévoient d'organiser des réunions avec des investisseurs.
2. La Conférence Virtuelle Sidoti Micro-Cap qui se déroulera les 14 et 15 août 2024. Oncocyte est programmée pour faire une présentation le mercredi 14 août, de 13h00 à 13h30 ET dans la Piste 3, et participera également à des réunions individuelles.
Les investisseurs intéressés à planifier des réunions avec l'équipe de direction d'Oncocyte peuvent contacter leur représentant Needham ou Sidoti ou joindre directement le contact IR de l'entreprise.
Oncocyte Corp. (Nasdaq: OCX), ein Unternehmen für molekulare Diagnosetechnologien, hat seine Teilnahme an zwei Investorenkonferenzen im August angekündigt. CEO Josh Riggs und CFO Andrea James werden das Unternehmen vertreten bei:
1. Der 9. jährlichen Needham Virtual MedTech & Diagnostics 1×1 Konferenz am 12.-13. August 2024, wo sie planen, Meetings mit Investoren abzuhalten.
2. Der Sidoti Micro-Cap Virtual Conference am 14.-15. August 2024. Oncocyte wird am Mittwoch, den 14. August, von 13:00 bis 13:30 Uhr ET in Track 3 präsentieren und ebenfalls an One-on-One-Meetings teilnehmen.
Investoren, die an der Planung von Meetings mit dem Management-Team von Oncocyte interessiert sind, können ihren Needham- oder Sidoti-Vertreter kontaktieren oder sich direkt an den IR-Kontakt des Unternehmens wenden.
- Participation in two investor conferences indicates active engagement with the investment community
- One-on-one meetings with investors provide opportunities for in-depth discussions about the company
- None.
IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August:
- 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors.
- Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, as well as participate in one-on-one meetings. To join the presentation, please visit the webcast available online at: https://sidoti.zoom.us/webinar/register/WN_rqHxQLa-SP-7yjOy-Qditw
For additional details about the conferences or to schedule a one-on-one meeting with Oncocyte’s management team, please contact your Needham or Sidoti representative, or reach out directly to the company’s IR contact, jramson@pcgadvisory.com.
About Oncocyte
Oncocyte is a molecular diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When is Oncocyte (OCX) presenting at the Sidoti Micro-Cap Virtual Conference?
Which investor conferences is Oncocyte (OCX) participating in during August 2024?
How can investors schedule meetings with Oncocyte (OCX) management at these conferences?
Who will be representing Oncocyte (OCX) at the August 2024 investor conferences?
